Assistant Professor Kevin Alexander

Stanford University School of Medicine, Palo Alto (United States of America)

Membership: ESC Professional Member HFA Member

Follow

Contributor content

Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study

Presentation

Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study

Treatment patterns and clinical outcomes following diagnosis in patients with ATTR Amyloidosis - Results from the OverTTuRe Study

Presentation

Treatment patterns and clinical outcomes following diagnosis in patients with ATTR Amyloidosis - Results from the OverTTuRe Study

Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial

Presentation

Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial

ESC 365 is supported by

novartis

Explore sponsored resources